U.S. pharmaceutical company Pfizer (Pfizer) and German biotech company (BioNTech) jointly published preliminary clinical trial results on May 23, saying that children from 6 months to 5 years old were vaccinated with 3 doses of the new coronavirus pneumonia (COVID-19) jointly developed by them. -19) Vaccines are safe and effective.
Preliminary clinical trial results show that a third dose of the vaccine in a study of 1,678 children under the age of 5 in this wave of epidemics heated by a variant of the virus Omicron produced a significant immune response, and They were well tolerated and most side effects were mild to moderate.
The children in this group ranged from 6 months to 5 years old.
They did not receive the third dose until at least 2 months after the second dose.
The dose used in infants and children is only 3 micrograms, one-tenth of the adult vaccine dose.
Pfizer and BioNTech also stated in the statement that the vaccine was 80% effective in preventing infection with Omicron, but this was based on published results from a preliminary analysis.
Pfizer Chief Executive Albert Bourla said a final analysis would be released as soon as possible.
New topline data on 3 doses of only 3 μg of our #COVID19 vaccine in kids 6 mo to <5 yrs demonstrates a strong immune response & excellent safety profile. Efficacy of 80.3% observed in descriptive analysis; final efficacy data to be shared once available . https://t.co/IpDJqYXEUV
— Albert Bourla (@AlbertBourla) May 23, 2022
FDA independent panel to review
Hours after the companies released preliminary clinical trial results, the U.S. Food and Drug Administration (FDA) announced that its independent panel of experts would meet on June 15 to review applications from Pfizer and Moderna to allow their products to be used in young infants. with preschoolers.
FDA is not necessarily required to fully follow the recommendations of the expert committee, but generally does so.
Most countries have not yet approved vaccination for children under 5 years of age.
Many parents have expressed concern about the safety of vaccinating infants and children.
New crown pneumonia epidemic in the United States: The picture shows a 14-year-old boy in Missouri receiving the Pfizer vaccine at a clinic on May 12, 2021.
He was one of the first local teenagers to go to get the Pfizer vaccine.
(AP)
5 to 11 years old second injection approved
The U.S. Centers for Disease Control and Prevention (CDC) advisory panel said on May 19 that it supports the use of Pfizer’s new crown vaccine booster for children ages 5 to 11.
The CDC acted quickly on the panel's recommendations, opening the door for booster injections for elementary school students.
The vaccine is approved for use in people over the age of 12.
On the 17th, the FDA renewed the emergency use authorization of Pfizer's vaccine, approving it as a booster for people 5 to 11 years old.
They can receive a booster dose at least 5 months after the first dose.
The messenger ribonucleic acid (mRNA) new coronavirus vaccine known as the "Pfizer vaccine" was jointly developed by Pfizer and BioNTech.
The commercial Chinese name of the vaccine, called BNT162b2, in mainland China, Hong Kong and Macau is “Fubitai”, and its introduction and commercialization are the responsibility of Fosun Pharma, a partner of BioNTech.
Fosun-BioNTech and Pfizer-BioNTech both use BioNTech's technology to produce mRNA new coronavirus vaccines.
The Fubitx vaccine supplied to Hong Kong is produced in Germany by BioNTech.
British study: The efficacy of the fourth dose of the new crown vaccine is "far better than the third dose", and the antibody surges by about 2.2 times German media: China is considering the introduction of the Fubitai vaccine Israel research: the elderly vaccinated with 2 doses of Fubitai booster is more effective than only 1 dose in reducing death Epidemic rate | The world's first man was unable to be vaccinated due to illness, but he fought off the virus by vaccinating
